| Allyson Marie Servoss, MD | |
|
389 S 900 E, Salt Lake City, UT 84102-2310 | |
| (385) 282-2000 | |
| Not Available |
| Full Name | Allyson Marie Servoss |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 20 Years |
| Location | 389 S 900 E, Salt Lake City, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124282504 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | PENDING (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lds Hospital | Salt lake city, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
A memo circulated by Sen. Judd Gregg, R-N.H., spells out the arsenal of parliamentary maneuvers available to Republicans as they seek to stall the Senate's health debate, The New York Times reports on its Prescriptions blog. Gregg has a reputation as one of the GOP's "foremost experts on legislative war games."
Young football players may be at higher risk for stroke, according to a new study released in Journal of Child Neurology (JCN), published by SAGE.
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.
Reports from a case series study indicate that patients with major depression have high rates of treatment-resistant, residual insomnia, and that insomnia during the early remission phase could lead to recurrence of depressive episodes.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.
› Verified 7 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
A memo circulated by Sen. Judd Gregg, R-N.H., spells out the arsenal of parliamentary maneuvers available to Republicans as they seek to stall the Senate's health debate, The New York Times reports on its Prescriptions blog. Gregg has a reputation as one of the GOP's "foremost experts on legislative war games."
Young football players may be at higher risk for stroke, according to a new study released in Journal of Child Neurology (JCN), published by SAGE.
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.
Reports from a case series study indicate that patients with major depression have high rates of treatment-resistant, residual insomnia, and that insomnia during the early remission phase could lead to recurrence of depressive episodes.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Allyson Marie Servoss, MD 389 S 900 E, Salt Lake City, UT 84102-2310 Ph: (385) 282-2000 | Allyson Marie Servoss, MD 389 S 900 E, Salt Lake City, UT 84102-2310 Ph: (385) 282-2000 |
News Archive
A memo circulated by Sen. Judd Gregg, R-N.H., spells out the arsenal of parliamentary maneuvers available to Republicans as they seek to stall the Senate's health debate, The New York Times reports on its Prescriptions blog. Gregg has a reputation as one of the GOP's "foremost experts on legislative war games."
Young football players may be at higher risk for stroke, according to a new study released in Journal of Child Neurology (JCN), published by SAGE.
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.
Reports from a case series study indicate that patients with major depression have high rates of treatment-resistant, residual insomnia, and that insomnia during the early remission phase could lead to recurrence of depressive episodes.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.
› Verified 7 days ago
Virginia Jean Homewood, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3336 S 4155 W, Ste 301, Salt Lake City, UT 84120 Phone: 801-964-3865 Fax: 801-964-3894 | |
Alexandra L. Woodcock, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 30 N 1900 E Rm 2a200, Salt Lake City, UT 84132 Phone: 801-213-3716 | |
Lillian B. Boettcher, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 30 N 1900 E Rm 2b200, Salt Lake City, UT 84132 Phone: 801-581-7647 | |
Patricia Bearnson, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 4465 S 900 E Ste 275, Salt Lake City, UT 84124 Phone: 801-272-6100 Fax: 801-272-6101 | |
Eric C Nielson, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1220 East 3900 South, Suite 3e, Salt Lake City, UT 84124 Phone: 801-685-7188 Fax: 801-685-8116 | |
Susan T Horvath, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1140 E 3900 S Ste 400, Salt Lake City, UT 84124 Phone: 801-262-8666 Fax: 801-263-8821 | |
Carolyn Weaver Swenson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 50 N Medical Dr, Salt Lake City, UT 84132 Phone: 801-213-2995 |